Key Highlights

  • Loss per share was USD 0.76 against an estimate of a USD 0.56 loss.
  • Net loss was USD 22.27 million, against USD 13.78 million a year earlier.
  • Research and development expenses were USD 20.29 million, against USD 12.32 million.
  • Cash and marketable securities were USD 395.9 million at September 30.

Attovia Therapeutics (NASDAQ:ATTO) reported a third quarter 2026 loss per share of USD 0.76, against an estimate of a USD 0.56 loss and a USD 3.44 loss in the third quarter of 2025. Net loss was USD 22.27 million, compared with USD 13.78 million.

The loss from operations was USD 25.02 million, compared with USD 15.60 million. The report is the company's quarterly filing following its initial public offering, which closed on August 6, 2026.

Operating Expenses

Research and development expenses were USD 20.29 million, compared with USD 12.32 million, an increase of 65%. General and administrative expenses were USD 4.73 million, compared with USD 3.65 million, an increase of 30%. Total operating expenses were USD 25.02 million, against USD 15.96 million, an increase of 57%.

Personnel-related costs increased from USD 2.7 million to USD 3.5 million, primarily due to higher headcount to support its programs and higher share-based compensation expense from additional stock Options granted. Interest income increased from USD 1.9 million to USD 2.8 million as a result of higher Investment balances.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 61.61 million, compared with USD 43.37 million, and the loss per share attributable to common stockholders was USD 4.86, against USD 11.18. Total operating expenses were USD 67.23 million, against USD 48.69 million, and the loss from operations was USD 66.78 million, against USD 48.33 million.

Initial Public Offering and Cash Runway

On August 6, 2026, the company closed its initial public offering, issuing 19,550,000 shares of common stock at a price of USD 17.00 per share, inclusive of 2,550,000 additional shares. Net proceeds were approximately USD 305.3 million. The 2026 Plan, approved before the closing, became effective on August 3, 2026.

As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 395.9 million. Based on its current operating plan, the company estimates that these resources are sufficient to fund projected operating expenses and Capital Expenditure requirements into 2030, and for at least the next 12 months from the issuance of its financial statements. The filing also states that the company continues to require substantial additional capital to support further development.

The filing describes ATTO-1310 as an ATTOBODY-based therapeutic targeting interleukin-31 that completed dosing in a Phase 1 clinical trial in healthy volunteers and patients in the first quarter of 2026. It also describes ATTO-2306 and ATTO-1091 as programs in its portfolio.

The filing also notes that the Series C redeemable convertible preferred stock was recorded at Fair Value based on proceeds received, less issuance costs of USD 0.3 million.

Attovia Therapeutics Q3 2026 Earnings: Key Takeaways

Attovia Therapeutics reported a third quarter 2026 loss per share of USD 0.76 and a net loss of USD 22.27 million. Research and Development expenses were USD 20.29 million, and cash, cash equivalents and marketable securities were USD 395.9 million.